ATE470454T1 - Multimere konstrukte - Google Patents
Multimere konstrukteInfo
- Publication number
- ATE470454T1 ATE470454T1 AT05810409T AT05810409T ATE470454T1 AT E470454 T1 ATE470454 T1 AT E470454T1 AT 05810409 T AT05810409 T AT 05810409T AT 05810409 T AT05810409 T AT 05810409T AT E470454 T1 ATE470454 T1 AT E470454T1
- Authority
- AT
- Austria
- Prior art keywords
- fusion proteins
- domain
- flt
- multimerization
- neovascularization
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60888704P | 2004-09-13 | 2004-09-13 | |
US65820905P | 2005-03-04 | 2005-03-04 | |
PCT/US2005/032320 WO2006031689A2 (en) | 2004-09-13 | 2005-09-13 | Multimeric constructs |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE470454T1 true ATE470454T1 (de) | 2010-06-15 |
Family
ID=36060586
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05810409T ATE470454T1 (de) | 2004-09-13 | 2005-09-13 | Multimere konstrukte |
Country Status (16)
Country | Link |
---|---|
US (4) | US7928072B2 (de) |
EP (2) | EP1804835B9 (de) |
JP (1) | JP4944032B2 (de) |
CN (1) | CN101094688B (de) |
AT (1) | ATE470454T1 (de) |
BR (1) | BRPI0515264B1 (de) |
CY (1) | CY1114155T1 (de) |
DE (1) | DE602005021811D1 (de) |
DK (2) | DK1804835T3 (de) |
ES (2) | ES2407859T3 (de) |
HK (1) | HK1144663A1 (de) |
IL (2) | IL181839A0 (de) |
MX (1) | MX2007002942A (de) |
PL (2) | PL2229956T3 (de) |
PT (2) | PT2229956E (de) |
WO (1) | WO2006031689A2 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006031689A2 (en) * | 2004-09-13 | 2006-03-23 | Genzyme Corporation | Multimeric constructs |
WO2009042162A2 (en) | 2007-09-25 | 2009-04-02 | Genzyme Corporation | Compositions and methods for inhibiting interleukin pathways |
WO2009105669A2 (en) * | 2008-02-20 | 2009-08-27 | Genzyme Corporation | Angiogenesis inhibition |
WO2010019263A2 (en) * | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
US8697654B2 (en) | 2008-12-18 | 2014-04-15 | E I Du Pont De Nemours And Company | Peptide linkers for effective multivalent peptide binding |
SI2601214T1 (en) | 2010-08-06 | 2018-03-30 | Genzyme Corporation | VEGF antagonist compositions and their use |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
SI2726101T1 (sl) * | 2011-06-30 | 2018-12-31 | Genzyme Corporation | Inhibitorji aktivacije T-celic |
CN102399292A (zh) * | 2011-09-14 | 2012-04-04 | 盛剑鹏 | 重组干细胞因子与免疫球融合蛋白及其制备 |
US20130090375A1 (en) * | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
EP2807180B1 (de) | 2012-01-24 | 2018-03-28 | InterK Peptide Therapeutics Limited | Peptidmittel zur krebstherapie |
KR20150010957A (ko) * | 2012-04-25 | 2015-01-29 | 리가셉트, 엘엘씨 | 넓은 스펙트럼 erbb 리간드 결합 분자 및 그의 사용 방법 |
CN104411718B (zh) * | 2012-06-27 | 2018-04-24 | 弗·哈夫曼-拉罗切有限公司 | 用于制备包含特异性结合靶的至少一种结合实体的抗体Fc区缀合物的方法及其用途 |
CN104395339A (zh) | 2012-06-27 | 2015-03-04 | 弗·哈夫曼-拉罗切有限公司 | 用于选择并产生含有至少两种不同结合实体的定制高度选择性和多特异性靶向实体的方法及其用途 |
PT2968461T (pt) | 2013-03-13 | 2022-12-26 | Genzyme Corp | Proteínas de fusão que compreendem porções de ligação ao pdgf e ao vegf e seus métodos de utilização |
KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
BR112016017817A2 (pt) * | 2014-02-06 | 2017-10-10 | Genzyme Corp | composições e métodos para o tratamento e a prevenção de degeneração macular |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
GB201412748D0 (en) * | 2014-07-17 | 2014-09-03 | Levicept Ltd | Therapeutic use of P75NTR neurotrophin binding protein |
EP3253797A4 (de) * | 2015-02-03 | 2018-10-03 | Jyant Technologies, Inc. | Chemokin-immunoglobulin-fusionspolypeptide, zusammensetzungen daraus, verfahren zur herstellung und verwendung davon |
JP7088454B2 (ja) | 2015-12-30 | 2022-06-21 | コディアック サイエンシーズ インコーポレイテッド | 抗体および抗体複合体 |
KR102205830B1 (ko) * | 2017-10-26 | 2021-01-21 | 주식회사 큐로진생명과학 | 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물 |
US20220214340A1 (en) * | 2019-04-28 | 2022-07-07 | Leide Biosciences Co., Ltd. | Zipper structure that helps the formation of protein dimer and application thereof |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CN116370335A (zh) * | 2021-12-31 | 2023-07-04 | 康码(上海)生物科技有限公司 | 用于擦拭的病毒防护溶液以及病毒防护擦拭产品 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
EP0721983A1 (de) | 1988-01-22 | 1996-07-17 | ZymoGenetics, Inc. | Verfahren zur herstellung von biologisch-aktive Dimerpeptiden |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
JPH03233530A (ja) | 1990-02-09 | 1991-10-17 | Fuji Photo Optical Co Ltd | カメラ |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US20020032313A1 (en) | 1991-03-29 | 2002-03-14 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
DK1167384T3 (da) | 1992-10-28 | 2007-04-10 | Genentech Inc | Vaskular endotheliel cellevækstfaktor antagonister |
FR2702152B1 (fr) | 1993-03-03 | 1995-05-24 | Inst Nat Sante Rech Med | Virus recombinants et leur utilisation en thérapie génique. |
ES2230542T3 (es) | 1993-03-25 | 2005-05-01 | MERCK & CO., INC. | Inhibidor del factor de crecimiento celular endotelial vascular. |
JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
US6686200B1 (en) | 1993-08-31 | 2004-02-03 | Uab Research Foundation | Methods and compositions for the large scale production of recombinant adeno-associated virus |
EP0763103A4 (de) | 1994-04-28 | 1998-07-15 | Univ Michigan | Genverabreichender vektor aus in adenvirus verpackter plasmid-dna und eine verpackungszellinie |
US5827702A (en) | 1994-10-31 | 1998-10-27 | Genentech, Inc. | Ocular gene therapy |
US5767099A (en) | 1994-12-09 | 1998-06-16 | Genzyme Corporation | Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules |
US5650096A (en) | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5719131A (en) | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
US5910487A (en) | 1994-12-09 | 1999-06-08 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
US5939401A (en) | 1994-12-09 | 1999-08-17 | Genzyme Corporation | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules |
US5747471A (en) | 1994-12-09 | 1998-05-05 | Genzyme Corporation | Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules |
US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
US5948767A (en) | 1994-12-09 | 1999-09-07 | Genzyme Corporation | Cationic amphiphile/DNA complexes |
WO1996033280A1 (en) | 1995-04-17 | 1996-10-24 | Board Of Regents, The University Of Texas System | An adenovirus helper-virus system |
ATE445705T1 (de) | 1995-06-15 | 2009-10-15 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante adenoviren zur gentherapie |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Vegf結合性ポリペプチド |
CA2239366A1 (en) | 1996-01-05 | 1997-07-17 | Genetic Therapy, Inc. | Recombinase-mediated generation of adenoviral vectors |
US5994317A (en) | 1996-04-09 | 1999-11-30 | Vical Incorporated | Quaternary cytofectins |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US5935936A (en) | 1996-06-03 | 1999-08-10 | Genzyme Corporation | Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules |
DE69736860T2 (de) | 1996-09-24 | 2007-05-16 | Merck & Co., Inc. | Verbindungen zur hemmung der angiogenese durch gentherapie |
US5861397A (en) | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
WO1998031794A1 (fr) | 1997-01-17 | 1998-07-23 | Toa Gosei Co., Ltd. | Polypeptide liant le facteur vegf |
US5925628A (en) | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5912239A (en) | 1997-04-04 | 1999-06-15 | Genzyme Corporation | Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5948925A (en) | 1997-05-06 | 1999-09-07 | Genzyme Corporation | Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids |
US5942634A (en) | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
WO1998051323A1 (en) | 1997-05-13 | 1998-11-19 | The Regents Of The University Of California | Novel antiangiogenic peptide agents and their therapeutic and diagnostic use |
US5952916A (en) | 1998-05-28 | 1999-09-14 | Atras Auto Co., Ltd | Hammer-equipped emergency signal device |
EP1007714B1 (de) | 1997-06-03 | 2005-12-14 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Regulatorische sequenzen für die in-vivo-expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen. |
EP1009814B1 (de) | 1997-06-18 | 2007-08-29 | Merck & Co., Inc. (a New Jersey corp.) | Kdr, ein menschlicher tyrosin kinase rezeptor |
US5963622A (en) | 1997-07-29 | 1999-10-05 | 3Com Corporation | Mode signalling method and apparatus |
CA2303768C (en) | 1997-09-19 | 2009-11-24 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
WO1999057296A1 (en) | 1998-05-01 | 1999-11-11 | Genzyme Corporation | Partially deleted adenoviral vectors |
US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
US7083950B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
WO2000054813A2 (en) | 1999-03-15 | 2000-09-21 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
CN101433715B (zh) * | 1999-06-08 | 2013-04-17 | 里珍纳龙药品有限公司 | 具有改善的药物动力学特性的修饰嵌合多肽 |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US6821775B1 (en) | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
WO2002024234A2 (en) | 2000-09-20 | 2002-03-28 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
EP1349574A2 (de) | 2001-01-09 | 2003-10-08 | MERCK PATENT GmbH | Kombinationstherapie mit rezeptor-tyrosinkinase-hemmern und angiogenese-hemmer |
JP2005500083A (ja) * | 2001-01-25 | 2005-01-06 | ヒル−ロム サービシーズ,インコーポレイティド | 外科用テーブルのための油圧式アクチュエータ装置 |
DE10109855A1 (de) * | 2001-03-01 | 2002-09-12 | Stanislawski Thomas | Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung |
US7078411B2 (en) * | 2001-05-16 | 2006-07-18 | Umdnj (Univ Of Medicine & Dentist. Of Nj) | Phospholipid transfer protein (PLTP) and cholestoral metabolism |
CA2479167A1 (en) | 2002-03-20 | 2003-10-02 | University Of Florida Research Foundation, Inc. | Raav vector compositions and methods for the treatment of choroidal neovascularization |
CU23178A1 (es) | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
PL1606318T3 (pl) | 2003-03-26 | 2010-01-29 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Ulepszone białka fuzyjne FC |
WO2006031689A2 (en) * | 2004-09-13 | 2006-03-23 | Genzyme Corporation | Multimeric constructs |
BRPI0518105A (pt) | 2004-12-17 | 2008-11-04 | Genentech Inc | uso de antagonista da angiogênese e uso de anticorpo anti-vegf |
WO2010019263A2 (en) | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
-
2005
- 2005-09-13 WO PCT/US2005/032320 patent/WO2006031689A2/en active Application Filing
- 2005-09-13 PT PT101651594T patent/PT2229956E/pt unknown
- 2005-09-13 EP EP05810409A patent/EP1804835B9/de active Active
- 2005-09-13 EP EP10165159.4A patent/EP2229956B1/de active Active
- 2005-09-13 DE DE602005021811T patent/DE602005021811D1/de active Active
- 2005-09-13 ES ES10165159T patent/ES2407859T3/es active Active
- 2005-09-13 BR BRPI0515264A patent/BRPI0515264B1/pt not_active IP Right Cessation
- 2005-09-13 DK DK05810409.2T patent/DK1804835T3/da active
- 2005-09-13 DK DK10165159.4T patent/DK2229956T3/da active
- 2005-09-13 ES ES05810409T patent/ES2347340T3/es active Active
- 2005-09-13 JP JP2007531408A patent/JP4944032B2/ja active Active
- 2005-09-13 CN CN2005800386237A patent/CN101094688B/zh active Active
- 2005-09-13 MX MX2007002942A patent/MX2007002942A/es active IP Right Grant
- 2005-09-13 PL PL10165159T patent/PL2229956T3/pl unknown
- 2005-09-13 PL PL05810409T patent/PL1804835T3/pl unknown
- 2005-09-13 AT AT05810409T patent/ATE470454T1/de active
- 2005-09-13 PT PT05810409T patent/PT1804835E/pt unknown
-
2007
- 2007-03-11 IL IL181839A patent/IL181839A0/en not_active IP Right Cessation
- 2007-03-12 US US11/716,794 patent/US7928072B2/en active Active
-
2010
- 2010-12-01 HK HK10111185.0A patent/HK1144663A1/xx not_active IP Right Cessation
-
2011
- 2011-02-02 US US13/019,432 patent/US8658602B2/en active Active
- 2011-11-01 IL IL216095A patent/IL216095A/en not_active IP Right Cessation
-
2013
- 2013-07-17 CY CY20131100605T patent/CY1114155T1/el unknown
-
2014
- 2014-01-31 US US14/170,257 patent/US9815892B2/en active Active
-
2017
- 2017-10-17 US US15/785,775 patent/US20180155417A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE470454T1 (de) | Multimere konstrukte | |
EA202092093A1 (ru) | Композиции и способы перепрограммирования tcr с применением слитых белков | |
EA201270802A1 (ru) | Димерные слитые белки vstm3 и связанные с ними композиции и способы | |
DK2016102T3 (da) | Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse | |
WO2007097812A3 (en) | Therapeutic anti-her2 antibody fusion polypeptides | |
PA8738401A1 (es) | Proteinas de fusion de exendina | |
DE602004028337D1 (de) | Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion | |
TW200732350A (en) | Methods for generating monovalent IgG | |
WO2010003766A3 (en) | Multimeric tnf receptors | |
CY1119774T1 (el) | Χρηση πρωτεϊνων εξωκυτταρικου πεδιου του fgfr1 για την αγωγη καρκινων χαρακτηριζομενων απο εξαρτωμενες απο προσδεμα ενεργοποιητικες μεταλλαξεις στο fgfr2 | |
ATE505481T1 (de) | Fusionsproteine der tnf-superfamilie | |
AU2013211824A8 (en) | Fusion proteins comprising IgG2 hinge domains | |
WO2009097017A3 (en) | Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof | |
ATE511544T1 (de) | Selektion von wirtszellen mit proteinexpression auf hohem niveau | |
IN266806B (de) | ||
WO2010019263A3 (en) | Soluble flt constructs for treating cancers | |
ATE555383T1 (de) | Lösliche heterodimere rezeptoren und ihre verwendung | |
Lethbridge et al. | Immunological identification of the mouse H 4 histamine receptor on spinal cord motor neurons using a novel anti-mouse H 4 R antibody | |
WO2007051063A3 (en) | Gpcr expressing cell lines and antibodies | |
WO2010018444A3 (en) | An expression vector and a method thereof | |
TW200510456A (en) | Materials and methods relating to g-protein coupled receptor oligomers | |
ATE466874T1 (de) | Mit scytovirin der domäne 1 verwandte polypeptide | |
KR101795573B1 (ko) | 감미 단백질의 단맛 정도를 예측하는 방법 | |
AR068038A1 (es) | Polipeptidos de la hormona de crecimiento modificada | |
Tanase et al. | NEW TOOLS FOR DISCOVERING INHIBITORS OF THE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1804835 Country of ref document: EP |